Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

Industry Outlook: Down But Not Out

The contract services industry may not be as robust in 2009 as it has been in previous years, but it's not as bad as many people think.
Aug 1, 2009

The contract services industry may not be as robust in 2009 as it has been in previous years, but it's not as bad as many people think.

Issue Extra: Executive Roundtable—The Future of Pharmaceutical CMC Outsourcing

A Q&A with Pfizer CentreSource, moderated by Jim Miller.
Aug 1, 2009

A Q&A with Pfizer CentreSource, moderated by Jim Miller.

The Future of Pharmaceutical CMC Outsourcing

A roundtable with pharma majors Pfizer and Johnson & Johnson, moderated by Jim Miller.
Aug 1, 2009

A roundtable with pharma majors Pfizer and Johnson & Johnson, moderated by Jim Miller.

Penny-Wise, Pound-Foolish

Pharma companies that sell redundant facilities could endanger their supply chains.
Jul 8, 2009

Pharma companies that sell redundant facilities could endanger their supply chains.

Limits to Growth?

A major CRO ventures further into proprietary drug development.
Jun 8, 2009

A major CRO ventures further into proprietary drug development.

Penny-Wise, Pound-Foolish

Pharma companies that sell redundant facilities could endanger their supply chains.
Jun 2, 2009

Pharma companies that sell redundant facilities could endanger their supply chains.

Contract Organizations are the Sell of the Season

Despite the market downturn, private equity investors are lining up for pharmaceutical services.
May 6, 2009

Despite the market downturn, private equity investors are lining up for pharmaceutical services.

Limits to Growth?

A major CRO ventures further into proprietary drug development.
May 2, 2009

A major CRO ventures further into proprietary drug development.

The New Normal: The Changing Face of Pharma

When the business environment returns to "normal," our industry may appear quite different.
Apr 8, 2009

When the business environment returns to "normal," our industry may appear quite different.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here